Research & Development
How it Started
In 2017, after a life changing meeting with an ALS patient, Alon, NeuroSense’s CEO, was inspired to team up with world-renowned scientists and colleagues in order to research and develop an effective drug for ALS patients. The inspiration led to the establishment of NeuroSense, where we research the core pathologies of the diseases we address, and determine specific biological targets to pursue. We then identify relevant molecules that we believe will effectively modify these targets. Next, we combine the molecules in a synergistic manner in order to simultaneously target the multiple pathways involved in the complex pathologies of neurodegenerative diseases.
In parallel to the development of these drugs, we are expanding our research into relevant biomarkers, utilizing leading edge in vivo and in vitro methods.
NeuroSense’s therapy for ALS, PrimeC, is a unique formulation of a fixed-dose combination drug comprising ciprofloxacin and celecoxib, which aims to target multiple disease mechanisms, including microRNA dysregulation, iron accumulation and neuroinflammation.
Following successful preclinical studies, PrimeC has been tested in a phase 2a clinical trial in ALS patients, and NeuroSense is currently in preparation for a pivotal phase 2b/3 study with PrimeC.
NeuroSense is actively expanding and advancing our pipeline, including testing product candidates preclinically for the treatment of Parkinson’s disease and Alzheimer’s disease.
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a rare neurodegenerative disease characterized by the death of motor neurons. The disease causes gradual paralysis, which leads to progressive disability and eventually death, typically within two to five years from diagnosis.
Approximately 20,000 people in the U.S. and 450,000 worldwide are living with ALS. At any given moment, approximately 1 in 10,000 people worldwide is affected by ALS.
To date, no effective cure or treatment has been developed for ALS, primarily due to the complexity of mechanisms involved in the disease.
Thus far, the FDA has approved only two drugs to treat ALS, one of which is also approved by EMA. However, these existing treatments delay disease progression, or prolong survival, by only a few months.